All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA grants Oxi4503 rare pediatric disease designation for the treatment of children with AML

By Sumayya Khan

Share:

Sep 17, 2020


On September 16, 2020, the U.S. Food and Drug Administration (FDA) granted OXi4503 rare pediatric drug designation for the treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients.1

This designation was based on the phase Ib study (NCT02576301) of OXi4503 as a single agent and in combination with intermediate-dose cytarabine for adult patients with relapsed/refractory AML or myelodysplastic syndrome. Of the 26 evaluable patients with AML, ~17% reached complete remission and had a median overall survival of 528 days. The combination therapy showed a manageable toxicity profile, and 8.5 mg/m2 OXi4503 was identified as the maximum tolerated dose.1

OXi4503 is a vascular disrupting agent. It binds to tubulin at the colchicine binding site, thus disrupting the shape of tumor bone marrow endothelial cells, activating the cell cycle and making the tumor cells vulnerable to chemotherapy. It also directly kills tumor cells by myeloperoxidase activation of a fluorquinone cytotoxic mediator.2

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...